Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19377809 | 0.89 | SLC2A1 (0.52) | SLC2A1 | |
| SCHEMBL178883 | 0.82 | BCHE (0.56) | SLC2A1 | |
| SCHEMBL5376776 | 0.81 | SLC2A1 (0.55) | SLC2A1 | |
| SCHEMBL5381623 | 0.79 | SLC2A1 (0.51) | SLC2A1 | |
| SCHEMBL5383267 | 0.77 | SLC2A1 (0.40) | SLC2A1 | |
| SCHEMBL10069523 | 0.76 | SLC2A1 (0.60) | SLC2A1 | |
| SCHEMBL6034753 | 0.75 | SLC2A1 (0.48) | SLC2A1 | |
| SCHEMBL5382894 | 0.75 | SLC2A1 (0.48) | SLC2A1 | |
| SCHEMBL5376763 | 0.75 | SLC2A1 (0.48) | SLC2A1 | |
| SCHEMBL5385517 | 0.75 | NUDT1 (0.49) | SLC2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2007-09-13 | — | — | US | claimed |
| US-7220757-B2 | Compositions and methods for topical administration of 2-NH-heteroarylimidazoles | REPLIDYNE, INC. (US) | 2007-05-22 | — | — | US | claimed |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | BERGE JOHN | 2006-01-19 | — | — | US | claimed |
| EP-1581220-A2 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | Replidyne, Inc. (US) | 2005-10-05 | — | — | EP | claimed |
| US-6943175-B2 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. (US) | 2005-09-13 | — | — | US | claimed |
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. | 2004-07-29 | — | — | US | claimed |
| WO-2004052288-A2 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2004-06-24 | — | — | WO | claimed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2007-09-13 | — | — | US | disclosed |
| US-7220757-B2 | Compositions and methods for topical administration of 2-NH-heteroarylimidazoles | REPLIDYNE, INC. (US) | 2007-05-22 | — | — | US | disclosed |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | BERGE JOHN | 2006-01-19 | — | — | US | disclosed |
| EP-1581220-A2 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | Replidyne, Inc. (US) | 2005-10-05 | — | — | EP | disclosed |
| US-6943175-B2 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. (US) | 2005-09-13 | — | — | US | disclosed |
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | REPLIDYNE, INC. | 2004-07-29 | — | — | US | disclosed |
| WO-2004052288-A2 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | REPLIDYNE, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147548-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | NSUN3, TRMT1, NOP2 | SLC2A1 3689/4885 |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | SLC2A1 4328/4885 |
| US-20070213362-A1 | 2-NH-HETEROARYLIMIDAZOLES WITH ANTIBACTERIAL ACTIVITY | MET, ASNS, MRPS22 | SLC2A1 2998/4885 |
| US-20060014748-A1 | 2-NH-heteroarylimidazoles with antibacterial activity | TRMT1, NSUN3, NOP2 | SLC2A1 3868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.